On November 22, 2021 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021 (Press release, Portage Biotech, NOV 22, 2021, View Source [SID1234595957]). Dr. Walters will give an overview of Portage’s pipeline and status of current programs, including the company’s lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation is available now through the following link (here) as well as on the Investor section of the company’s website at View Source Management will also be hosting 1×1 meetings on November 30 and December 1.